Annual report and financial statements 2015 16 69 2 Taxation continued 2.3 Deferred tax continued The movements in deferred tax liabilities assets during the period are shown below: Other Property, short term plant and temporary equipment Pensions differences Total m m m m Current period At 2 February 2015 428 8 5 415 Credited charged to profit for the period 36 6 5 37 Charged to other comprehensive income and equity 47 4 51 At 31 January 2016 392 33 4 429 Prior period At 3 February 2014 456 2 24 430 Credited charged to loss for the period 28 21 7 Credited to other comprehensive income and equity 6 2 8 At 1 February 2015 428 8 5 415 The analysis of net deferred tax liabilities are as follows: 2016 2015 m m Net deferred tax liabilities to be settled after more than 12 months 427 358 Net deferred tax liabilities to be settled within 12 months 2 57 429 415 3 Operating assets 3.1 Accounting policies Intangible assets Goodwill Goodwill arising on a business combination is not amortised but is reviewed for impairment on an annual basis or more frequently if there are indicators that it may be impaired.
Goodwill is allocated to cash generating units that will benefit from the synergies of the business combination for the purpose of impairment testing.
Brands Brands acquired through a business combination are recognised at their fair value at the acquisition date and amortised to profit or loss on a straight-line basis over their estimated useful economic life.
During the prior year the Group disposed of 15m of fully written down brands relating to Kiddicare.
Software development costs Costs that are directly attributable to the creation of identifiable software, which meet the development asset recognition criteria as laid out in IAS 38 Intangible assets are recognised as intangible assets.
Direct costs include consultancy costs, the employment costs of internal software developers, and borrowing costs.
All other software development and maintenance costs are recognised as an expense as incurred.
Software development assets are held at historic cost less accumulated amortisation and impairment, and are amortised over their estimated useful lives 3 to 10 years on a straight-line basis.
Licences Separately acquired pharmaceutical licences and software licences are recognised at historic cost less accumulated amortisation and impairment.
Those acquired in a business combination are recognised at fair value at the acquisition date.
Pharmaceutical licences and software licences are amortised over their useful lives 3 to 10 years on a straight-line basis or over the life of the licence if shorter.
